[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"combined-pulmonary-fibrosis-and-emphysema\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:combined-pulmonary-fibrosis-and-emphysema":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":4,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":17,"phases":4,"briefSummary":18,"conditions":19,"keywords":23,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":38,"locationsCount":4},"100483281","inhaled-treprostinil-expanded-access-program-in-pulmonary-hypertension-associated-with-interstitial-lung-disease-100483281",false,"NCT05572996","Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n1. Patient consent\n2. Males and females aged 18 years old or older\n3. PH-ILD diagnosis:\n\n   * Confirmed diagnosis of Group 3 PH by Right Heart Catheterization (RHC):\n\n     \\- mPAP \\> 20 mmHg with PAWP ≤ 15 mmHg and PVR ≥ 2 WU and\n   * Confirmed diagnosis of diffuse parenchymal lung disease based on imaging (any form of ILD or CPFE)\n\nExclusion Criteria:\n\n1. Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD\n2. Use of concomitant PAH drugs contraindicated for PH-ILD (ambrisentan and riociguat)\n3. Use of any concomitant investigational drug","ALL","18 Years","EXPANDED_ACCESS","This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.",[20,21,22],"Pulmonary Hypertension","Interstitial Lung Disease","Combined Pulmonary Fibrosis and Emphysema",[24,25,26,27,28,29,30,31,32],"Inhaled Treprostinil","Tyvaso","EAP","Expanded Access","Early Access","Compassionate Use","Named Patient Program","NPP","PH-ILD","AVAILABLE","2022-10-05",{"date":36,"type":37},"2022-10-10","ACTUAL",{"name":39,"class":40},"Ferrer Internacional S.A.","INDUSTRY"]